Collection: Sports & Exercise
-
Pickleball Kit (Classic Butterfly)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Classic Purple Ribbon)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Modern Purple Ribbon)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Pure Purple)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Pure Star)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Bubble Ribbon)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Butterfly)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Corner)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Floral)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Lux Floral)
Regular price $38.32 USDRegular priceUnit price per -
Pickleball Kit (Purple Sky)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Purple Sleepy Emoji)
Regular price $38.32 USDRegular priceUnit price per -
Pickleball Kit (Purple Two Tone)
Regular price $64.00 USDRegular priceUnit price per -
Pickleball Kit (Warrior)
Regular price $64.00 USDRegular priceUnit price per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
